Issah Younossi

Association of work productivity with clinical and patient-reported factors in patients infected with hepatitis C virus.

Patients with HCV infection have reduced work productivity (WP), in terms of both presenteeism (impairment in work productivity while working) and absenteeism (productivity loss due to absence from work). The aim of this study was to identify clinical and patient‐reported factors that are predictive of WP in HCV‐infected patients. HCV‐infected patients enrolled in clinical trials completed 3 PRO questionnaires (CLDQ‐HCV, SF‐36 and FACIT‐F) and one work productivity (WPAI:SHP) questionnaire. In employed subjects, work productivity and its absenteeism and presenteeism components were calculated using WPAI:SHP instrument. Of 4121 HCV‐infected patients with work productivity data, 2480 (60.2%) reported to be employed, and of those, 2190 had completed all PRO questionnaires before treatment initiation. Of the study cohort, 519/2190 (23.7%) had severe work impairment. In multiple linear regression analysis, work productivity was predicted by lower scores in activity/energy domain of CLDQ‐HCV, physical well‐being domain of FACIT‐F, worry domain of CLDQ‐HCV and role physical domain of SF‐36 (all P < 0.0005). Furthermore, presenteeism was independently predicted by the activity/energy of CLDQ‐HCV, physical well‐being of FACIT‐F, worry domain of CLDQ‐HCV, role physical scale of SF‐36 and fatigue scale of FACIT‐F (P < 0.002). Finally, absenteeism was independently predicted by physical well‐being scale of FACIT‐F and role physical scale of SF‐36 (all P < 0.002). Clinically, work productivity impairment was predicted by the presence of cirrhosis, anxiety, depression and clinically overt fatigue (P < 0.01). Thus, the most important drivers of WP in HCV are impairment of physical aspects of PROs and clinical history of depression, anxiety, fatigue and cirrhosis.

Variables Associated With Inpatient and Outpatient Resource Utilization Among Medicare Beneficiaries With Nonalcoholic Fatty Liver Disease With or Without Cirrhosis.

Background: Nonalcoholic fatty liver disease (NAFLD) is one of the leading causes of chronic liver disease worldwide with tremendous clinical burden. The economic burden of NAFLD is not well studied. Goal: To assess the economic burden of NAFLD. Study: Medicare beneficiaries (January 1, 2010 to December 31, 2010) with NAFLD diagnosis by International Classification of Diseases, Ninth Revision codes in the absence of other liver diseases were selected. Inpatient and outpatient resource utilization parameters were total charges and total provider payments. NAFLD patients with compensated cirrhosis (CC) were compared with decompensated cirrhosis (DC). Results: A total of 976 inpatients and 4742 outpatients with NAFLD were included—87% were white, 36% male, 30% had cardiovascular disease (CVD) or metabolic syndrome conditions, and 12% had cirrhosis. For inpatients, median total hospital charge was

Gene expression profile associated with superimposed non-alcoholic fatty liver disease and hepatic fibrosis in patients with chronic hepatitis C

36,289. NAFLD patients with cirrhosis had higher charges and payments than noncirrhotic NAFLD patients (

Direct and Indirect Economic Burden of Chronic Liver Disease in the United States

61,151 vs.

Mental and Emotional Impairment in Patients With Hepatitis C is Related to Lower Work Productivity

33,863 and

Gene expression profiles associated with depression in patients with chronic hepatitis C (CH‐C)

18,804 vs.

Functional pathway analysis of genes associated with response to treatment for chronic hepatitis C

10,146, P<0.001). Compared with CC, NAFLD patients with DC had higher charges and payments (P<0.02). For outpatients, median total charge was

Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3

9,011. NAFLD patients with cirrhosis had higher charges and payments than noncirrhotic NAFLD patients (

Gene expression profiles associated with anaemia and ITPA genotypes in patients with chronic hepatitis C (CH‐C)

12,049 vs.

Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir

8,830 and